Division of Gastroenterology and HepatologyMayo ClinicRochesterMN.
Departamento de GastroenterologiaEscuela de MedicinaPontificia Universidad Catolica de ChileSantiagoChile.
Hepatology. 2021 Feb;73(2):571-585. doi: 10.1002/hep.31256. Epub 2020 Oct 30.
Alcoholic hepatitis (AH) is diagnosed by clinical criteria, although several objective scores facilitate risk stratification. Extracellular vesicles (EVs) have emerged as biomarkers for many diseases and are also implicated in the pathogenesis of AH. Therefore, we investigated whether plasma EV concentration and sphingolipid cargo could serve as diagnostic biomarkers for AH and inform prognosis to permit dynamic risk profiling of AH subjects.
EVs were isolated and quantified from plasma samples from healthy controls, heavy drinkers, and subjects with end-stage liver disease (ESLD) attributed to cholestatic liver diseases and nonalcoholic steatohepatitis, decompensated alcohol-associated cirrhosis (AC), and AH. Sphingolipids were quantified by tandem mass spectroscopy. The median plasma EV concentration was significantly higher in AH subjects (5.38 × 10 /mL) compared to healthy controls (4.38 × 10 /mL; P < 0.0001), heavy drinkers (1.28 × 10 /mL; P < 0.0001), ESLD (5.35 × 10 /mL; P < 0.0001), and decompensated AC (9.2 × 10 /mL; P < 0.0001) disease controls. Among AH subjects, EV concentration correlated with Model for End-Stage Liver Disease score. When EV counts were dichotomized at the median, survival probability for AH subjects at 90 days was 63.0% in the high-EV group and 90.0% in the low-EV group (log-rank P value = 0.015). Interestingly, EV sphingolipid cargo was significantly enriched in AH when compared to healthy controls, heavy drinkers, ESLD, and decompensated AC (P = 0.0001). Multiple sphingolipids demonstrated good diagnostic and prognostic performance as biomarkers for AH.
Circulating EV concentration and sphingolipid cargo signature can be used in the diagnosis and differentiation of AH from heavy drinkers, decompensated AC, and other etiologies of ESLD and predict 90-day survival permitting dynamic risk profiling.
酒精性肝炎(AH)是通过临床标准诊断的,尽管有几种客观评分有助于进行风险分层。细胞外囊泡(EVs)已成为许多疾病的生物标志物,并且也与 AH 的发病机制有关。因此,我们研究了血浆 EV 浓度和鞘脂类货物是否可以作为 AH 的诊断生物标志物,并提供预后信息,以便对 AH 患者进行动态风险评估。
从健康对照组、大量饮酒者以及终末期肝病(ESLD)患者的血浆样本中分离和定量 EVs,这些患者的 ESLD 归因于胆汁淤积性肝病和非酒精性脂肪性肝炎、失代偿性酒精性相关肝硬化(AC)和 AH。通过串联质谱法定量鞘脂。与健康对照组(4.38×10 /mL;P<0.0001)、大量饮酒者(1.28×10 /mL;P<0.0001)、ESLD(5.35×10 /mL;P<0.0001)和失代偿性 AC(9.2×10 /mL;P<0.0001)相比,AH 患者的血浆 EV 浓度中位数明显更高。在 AH 患者中,EV 浓度与终末期肝病模型评分相关。当 EV 计数以中位数分为两部分时,AH 患者 90 天的生存率在高 EV 组为 63.0%,在低 EV 组为 90.0%(对数秩 P 值=0.015)。有趣的是,与健康对照组、大量饮酒者、ESLD 和失代偿性 AC 相比,AH 患者的 EV 鞘脂货物明显富集(P=0.0001)。多种鞘脂作为 AH 的生物标志物具有良好的诊断和预后性能。
循环 EV 浓度和鞘脂货物特征可用于 AH 的诊断和与大量饮酒者、失代偿性 AC 和其他 ESLD 病因的区分,并预测 90 天生存率,从而实现动态风险评估。